A Phase 2/3 interventional study of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) and Placebo in Ovarian Neoplasms and Ascites, sponsored by Sanofi. Completed at 9 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-01.
Sponsored by Sanofi · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Ovarian Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Ovarian Neoplasms · Sanofi.
Among the 14 studies in Ovarian Neoplasms by Sanofi, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2006, is the only one in phase 2/3, and was the 3rd registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →None of the 14 studies in Ovarian Neoplasms by Sanofi is open now. The open studies under Ovarian Neoplasms, anywhere →
Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 1
First in 1999; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is close to the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 47 across the 13 interventional studies, 30 across the 1 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Ovarian Neoplasms by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer.
Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) to placebo treatment on repeat paracentesis in symptomatic malignant ascites in participants with advanced ovarian cancer
Secondary objectives: Safety, tolerability, paracentesis-related parameters, participant-reported outcome.
The study included:
Criteria for discontinuation included:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who met the following criteria were eligible to participate in this study.
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period. In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study.
Drug: Placebo · Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period. In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study.
Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
Time to Repeat Paracentesis (TRP)
TRP was defined as the number of days between the date of randomization and the date of the first post-randomization paracentesis. For participants who did not undergo a postrandomization paracentesis on study, TRP was calculated from randomization to the end of the double-blind treatment period.
Time frame: From Day 1 up to 6 months from randomization
Area Under the Curve (AUC) for Participant Assessed Ascites Impact Measure (AIM)
AIM 4 symptoms (abdominal discomfort, abdominal bloating, abdominal pain, and ability to move normally) are scored from 0 to 5, where higher scores represent worst outcomes. An AIM total score ranges from 0-20. A plot for (The AIM questionnaire total score - Baseline score) versus time were generated. AIM AUC represents the overall improvement (scored positive) if the area is below the baseline value or worsening (scored negative) if the area is above the baseline. AIM AUC for a participant is the sum of individual areas representing improvement (+) or worsening (-).
Time frame: From Day 1 up to 60 days from randomization to the first postrandomization paracentesis
60-Day Frequency of Paracentesis (FOP)
60-Day FOP was defined as the total number of paracenteses performed within the first 60 days after randomization during the double blind treatment period.
Time frame: From Day 1 up to 60 days from randomization
Plasma Levels of Free and VEGF-bound Aflibercept
Free aflibercept and VEGF-bound aflibercept plasma concentrations were measured by separate enzyme-linked immunosorbent assay (ELISA). The limit of quantitation of free aflibercept was 15.6 ng/mL, and of VEGF-bound aflibercept was 43.9 ng/mL. Peak free aflibercept was estimated at the end of Cycle 1 (C1) administration. The median free and VEGF-bound trough concentrations were determined for each participant beyond Cycle 3 (C3), then mean values were estimated from these median values.
Time frame: Following every biweekly treatment administration up to 60 days after treatment discontinuation
Fifty-eight (58) participants from a total of 23 sites in 7 countries were enrolled in the study.
| Milestone | Placebo | Aflibercept |
|---|---|---|
| Started | 26 | 29 |
| Safety | 25 | 30 |
| Completed | 0 | 0 |
| Not completed | 26 | 29 |
| Withdrew: Disease progression | 10 | 13 |
| Withdrew: Adverse event | 5 | 5 |
| Withdrew: Subject request | 0 | 1 |
| Withdrew: Withdrew db and continued to ol | 11 | 10 |
| Milestone | Placebo | Aflibercept |
|---|---|---|
| Started | 11 | 10 |
| Ongoing treatment | 1 | 0 |
| Completed | 0 | 0 |
| Not completed | 11 | 10 |
| Withdrew: Disease progression | 8 | 7 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Worsening dyspnea | 0 | 1 |
| Withdrew: Ongoing treatment | 1 | 0 |
TRP was defined as the number of days between the date of randomization and the date of the first post-randomization paracentesis. For participants who did not undergo a postrandomization paracentesis on study, TRP was calculated from randomization to the end of the double-blind treatment period.
| days | Placebo | Aflibercept |
|---|---|---|
| Time to Repeat Paracentesis (TRP) | 23.3 ± 7.70 | 55.1 ± 7.25 |
AIM 4 symptoms (abdominal discomfort, abdominal bloating, abdominal pain, and ability to move normally) are scored from 0 to 5, where higher scores represent worst outcomes. An AIM total score ranges from 0-20. A plot for (The AIM questionnaire total score - Baseline score) versus time were generated. AIM AUC represents the overall improvement (scored positive) if the area is below the baseline value or worsening (scored negative) if the area is above the baseline. AIM AUC for a participant is the sum of individual areas representing improvement (+) or worsening (-).
| (units on a 4-symptom scale)*day | Placebo | Aflibercept |
|---|---|---|
| Area Under the Curve (AUC) for Participant Assessed Ascites Impact Measure (AIM) | 29.8 ± 148.07 | 405.3 ± 143.21 |
60-Day FOP was defined as the total number of paracenteses performed within the first 60 days after randomization during the double blind treatment period.
| paracentesis | Placebo | Aflibercept |
|---|---|---|
| 60-Day Frequency of Paracentesis (FOP) | 5.1 ± 0.69 | 2.7 ± 0.65 |
Free aflibercept and VEGF-bound aflibercept plasma concentrations were measured by separate enzyme-linked immunosorbent assay (ELISA). The limit of quantitation of free aflibercept was 15.6 ng/mL, and of VEGF-bound aflibercept was 43.9 ng/mL. Peak free aflibercept was estimated at the end of Cycle 1 (C1) administration. The median free and VEGF-bound trough concentrations were determined for each participant beyond Cycle 3 (C3), then mean values were estimated from these median values.
| μg/mL | Double Blind (DB) Period | Open-Label (OL) Period |
|---|---|---|
| Peak Free Aflibercept (C1) (N=20, N=15) | 69.8 ± 29.7 | 62.1 ± 29.5 |
| Trough Free Aflibercept (Beyond C3) (N=15, N=19) | 5.33 ± 3.67 | 5.10 ± 5.29 |
| Trough Bound Aflibercept (Beyond C3) (N=16, N=17) | 3.02 ± 1.29 | 3.49 ± 1.48 |
Collected over From treatment initiation to October 30, 2009. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 18/25 (72%) | 22/25 (88%) |
| Aflibercept | — | 27/30 (90%) | 28/30 (93.3%) |
| Event | Placebo | Aflibercept |
|---|---|---|
| Disease progressionGeneral disorders | 8/25 | 10/30 |
| VomitingGastrointestinal disorders | 3/25 | 6/30 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/25 | 6/30 |
| DehydrationMetabolism and nutrition disorders | 4/25 | 4/30 |
| Abdominal painGastrointestinal disorders | 0/25 | 3/30 |
| Small intestinal obstructionGastrointestinal disorders | 1/25 | 3/30 |
| AscitesGastrointestinal disorders | 2/25 | 1/30 |
| Intestinal obstructionGastrointestinal disorders | 2/25 | 0/30 |
| FatigueGeneral disorders | 2/25 | 0/30 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 2/25 | 1/30 |
| Event | Placebo | Aflibercept |
|---|---|---|
| VomitingGastrointestinal disorders | 13/25 | 19/30 |
| FatigueGeneral disorders | 14/25 | 10/30 |
| DiarrhoeaGastrointestinal disorders | 5/25 | 12/30 |
| Oedema peripheralGeneral disorders | 10/25 | 11/30 |
| NauseaGastrointestinal disorders | 9/25 | 11/30 |
| AnorexiaMetabolism and nutrition disorders | 9/25 | 8/30 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/25 | 6/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/25 | 8/30 |
| AstheniaGeneral disorders | 3/25 | 7/30 |
| Back painMusculoskeletal and connective tissue disorders | 4/25 | 7/30 |
| Age, Customized(participants) | Placebo | Aflibercept | Total |
|---|---|---|---|
| < 35 years | 0 | 1 | 1 |
| >=35 to <45 years | 5 | 1 | 6 |
| >=45 to <55 years | 10 | 7 | 17 |
| >=55 to <65 years | 4 | 11 | 15 |
| >=65 to <75 years | 6 | 7 | 13 |
| >=75 years | 1 | 2 | 3 |
| Sex: Female, Male(Participants) | Placebo | Aflibercept | Total |
|---|---|---|---|
| Female | 26 | 29 | 55 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Placebo | Aflibercept | Total |
|---|---|---|---|
| Caucasian | 19 | 22 | 41 |
| Black | 1 | 0 | 1 |
| Asian, Oriental | 6 | 7 | 13 |
The record gives a start of Jul 2006, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 3 years 3 months after primary completion. A results delay was requested in Jul 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept